Floatz logo

Cyclophosphamide

PD-L1 Positive

Gilead SciencesSmall moleculePhase 3Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the PD-L1 Positive cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Gilead Sciences
Phase 3B
Epirubicin
Gilead Sciences
Phase 3B
Carboplatin
Gilead Sciences
Phase 3B
Limertinib
Shanghai Chest Hospital
Phase 2CCC
DACARBAZINE
The First Hospital of Jilin University
Phase 2CCC

View all 12 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →